Efficacy of 500µg Roflumilast Once Daily Versus Placebo Over 12 Weeks in Patients With Diabetes Mellitus Type 2. A Double Blind, Parallel Group, Proof of Concept Clinical Study

• Status: Completed
• Trial end date: 2008-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is a proof of concept study to confirm in a standardized manner the therapeutic efficacy of roflumilast in type 2 diabetes mellitus patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca

Criteria

Inclusion Criteria:

• given written informed consent

• patients with diagnosis of type 2 diabetes according to American Diabetes Association (ADA) criteria and inadequately controlled on diet and exercise alone

• HbA1c at baseline: ≥7.5 percent to 8.5 percent (up to 9 percent in Mexico, Ukraine and Romania)

• BMI between ≥26 and ≤35 kg/m2

• willingness of patient to check his/her blood glucose with equipment provided by the sponsor during the treatment phase in case of hypo-/hyperglycemia episodes

• willingness to adhere to the physician's advise to comply with diet and exercise

Main Exclusion Criteria:

• patients diagnosed with type 1 diabetes or diabetes secondary to pancreatitis or resection of pancreas

• patients diagnosed with hemoglobinopathies, hemolytic anemia or other diseases which interfere with HbA1c measurement

• non-euthyroid patients or patients with a non-controlled hypo- or hyperthyroidism

• reported gain or loss of more than 5 percent of body weight within the last 2 months prior to V0

• treatment with any diabetes medication prior to V0

• treatment with any weight-loss medication within 3 months prior to V0

• treatment with any not allowed medication or nutrition additives

• clinically relevant abnormal laboratory values suggesting an unknown disease and requiring further clinical evaluation (as assessed by the investigator)

• clinically significant cardiac abnormalities (diagnosed clinically, or by X-ray/ECG) that were not related to type 2 diabetes mellitus and that required further evaluation

• participation in a clinical study with study medication for weight loss or type 2 diabetes

Patients were randomized after 2 weeks of the baseline period, if the following criteria were fulfilled:

• judged to be clinically stable

• tablet compliance ≥80 percent and ≤125 percent

• HbA1c in the range of 7.5 percent to 8.5 percent (up to 9 percent in Mexico, Ukraine and Romania) tested at V0 by the central laboratory